Contineum Therapeutics Income Statement (2023-2025) | CTNM

1Y3Y5Y7Y10YAll
Download Data
Income Statement Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025
Revenue & cost
Revenue -0.09M-0.12M
Operating items
Research & Development 3.63M9.46M6.50M8.01M7.78M7.90M9.73M13.02M
Selling, General & Administrative 1.48M1.60M1.57M1.66M2.15M3.04M3.25M4.03M
Operating Expenses 5.12M11.06M8.07M9.68M9.93M10.94M12.97M17.05M
Operating Income -5.12M38.94M-8.07M-9.68M-9.93M-10.94M-12.97M-17.05M
EBIT -5.12M38.94M-8.07M-9.68M-9.93M-10.94M-12.97M-17.05M
Non-operating items
Interest & Investment Income 0.40M0.68M1.74M1.79M1.64M2.00M2.74M2.53M
Other Non Operating Income -0.02M-0.08M-0.04M-0.05M-0.01M-0.08M-0.03M1.13M
Non Operating Income 0.29M3.36M1.70M1.75M1.51M1.94M2.71M2.48M
Net income details
EBT -4.82M42.30M-6.37M-7.93M-8.42M-9.01M-10.27M-14.56M
Tax Provisions 0.73M-0.12M-0.16M
Profit After Tax -4.82M41.56M-6.25M-7.77M-8.42M-9.01M-10.30M-14.60M
Income from Continuing Operations -4.82M41.57M-6.25M-7.77M-8.42M-9.01M-10.27M-14.56M
Consolidated Net Income -4.82M41.57M-6.25M-7.77M-8.42M-9.01M-10.27M-14.56M
Income towards Parent Company -4.82M41.57M-6.25M-7.77M-8.42M-9.01M-10.27M-14.56M
Net Income towards Common Stockholders -4.82M41.57M-6.25M-7.77M-8.42M-9.01M-10.27M-14.56M
Additional items
EPS (Basic) -2.122.56-2.69-0.53-3.55-0.39-0.40-0.57
EPS (Weighted Average and Diluted) -0.10-2.69-0.35-0.96-0.40-0.57
Shares Outstanding (Weighted Average) 18.26M18.26M25.72M25.72M25.78M25.87M25.87M28.04M
EBITDA -4.76M41.51M-6.28M-7.57M-8.58M-9.08M-9.58M-15.05M
Interest Expenses 0.09M0.12M
Shares Outstanding 11.89M15.22M15.91M15.91M15.91M25.72M25.74M25.85M25.87M25.92M29.18M
Tax Rate 1.721.852.03